View all 108,287 employees
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
Website https://www.pfizer.com/?source=Linkedin Industry Pharmaceutical Manufacturing Company size 10,001+ employees Headquarters New York, New York Type Public Company Specialties To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe and effective and affordable medicines and health care services to the people who need them. LocationsNew York
New York, New York 10017, US
Get directionsMumbai
Mumbai, Maharastra 400102, IN
Get directions1 Giralda Farms
Madison, NJ 07940, US
Get directionsLittleconnell
Newbridge, County Kildare, IE
Get directions280 Shennecossett Rd
Groton, CT 06340, US
Get directionsNo. 177, Sec 2, Zhong Zheng E. Rd.
New Taipei City, New Taipei City 251, TW
Get directions38-42 Wharf Rd
Sydney, NSW 2114, AU
Get directions1 Burtt Rd
Andover, MA 01810, US
Get directionsRijksweg 12
Puurs, Flemish Region 2870, BE
Get directions85 Bute Ln
Sandton, Gauteng 2196, ZA
Get directions500 Arcola Rd
Collegeville, PA 19426, US
Get directions1200 Parkdale Rd
Rochester, MI 48307, US
Get directions1025 Boulevard Marcel-Laurin
Montreal, QC H4R 1J6, CA
Get directionsAbilay han dangili 141
Almaty, Almaty Oblysy 050000, KZ
Get directions31 Tuas South Ave 6
Singapore, Singapore 637578, SG
Get directions1040 Swabia Ct
Durham, NC 27703, US
Get directionsArye Shenkar 9
Herzliya, Tel Aviv 46725, IL
Get directions110
JUNGGU, Seoul, KR
Get directionsVia Isonzo, 71
Latina, Laz. 04100, IT
Get directionsPfizer reposted this
Albert Bourla Albert Bourla is an Influencer 2wOnly in America could a scientist from Greece rise to lead one of the world's great scientific companies. I have never taken that for granted, and I think about it even more as America turns 250. This country has always had a gift for making bold bets that changed the world. The moon landing, the internet, the Human Genome Project. These milestones and so many others came from generations of Americans who chose to invest in science and a belief in a brighter future. Today, America faces a choice once again. New tools in biology, from how we design medicines to how we manufacture them, have already expanded what is possible for patients. AI will shape what comes next in ways we are only beginning to see. Tools alone don’t determine outcomes. It requires investing in innovation. It requires committing to shaping future opportunities. The coming decade will determine where great new discoveries occur and where the most ambitious scientists build their life's work. I want the answer to be here. Other nations have serious scientific ambition, and I welcome it. Competition never scared America. It has always made us better. You don’t win races by trying to hold others back. You win by running faster, running harder. America’s opportunity is to continue leading by investing more, building more and moving faster. Pfizer will continue doing its part. We were founded in New York in 1849, and we have been competing and betting on American science ever since. We are driven by a single purpose: delivering breakthroughs that change patients' lives. My wish for America's 250th birthday is simple. Let us choose, once again, to bet on ourselves – and on science. No nation has ever done it better. #A250
7,097,553 followers
3w EditedOur Chief Scientific Officer, Chris Boshoff, MD, PhD, FMedSci, sat down with Scientific American to reflect on the state of American science and why he's optimistic about what's ahead. https://lnkd.in/dSg3R6q6
Chris Boshoff, MD, PhD, FMedSci 3wThe convergence of biology, genomics, data science, and engineering is driving a new age of discovery that would have been unimaginable even a decade ago. My advice for early-career scientists: stay curious about biology and learn from failure. Techniques will change, but a deep grasp of disease mechanisms will remain essential. That conviction — about what endures and why it matters — is what I brought to a conversation with Scientific American for their "The Young American Scientists" series: where American science stands right now, what gives me optimism, and what I think we need to protect. Read here: https://lnkd.in/e26-cuRY Next week, America turns 250 — and at its best, this country has always been a story of restless curiosity, the freedom to ask hard questions and refuse easy answers. We saw that spirit alive again in the extraordinary public response to Artemis II: people didn't just notice, they felt it, because humans are wired to respond to audacious ambition. Sustained investment in foundational research is how civilizations turn curiosity into destiny. And scientists have a role too: not just in the laboratory, but in telling the story of why the work matters, in language that invites everyone in. The next 250 years belong to the questions we have the courage to ask today. #Science #Research #Pfizer
7,097,553 followers
1moPfizer is advancing our commitment to deliver transformative medicines for people living with cancer through a new strategic global collaboration with Innovent Biologics. Together, we will work to accelerate the research and development of 12 potentially promising early-stage and 𝑑𝑒 𝑛𝑜𝑣𝑜 oncology programs spanning antibody-drug conjugates (ADCs) and multi-specific antibodies with differentiated designs and novel mechanisms. By combining Pfizer Oncology’s global development, regulatory and commercial expertise with Innovent’s scientific discovery and early clinical capabilities, we aim to accelerate the delivery of next-generation breakthroughs for patients in the U.S. and around the world. This collaboration strengthens Pfizer’s Oncology pipeline and supports our long-term ambition to redefine standards of care and help address areas of significant unmet need in cancer treatment. https://lnkd.in/dXdvQ2cc #Pfizer #Oncology #CancerResearch #Biotech #Innovation
…more Play Video Video Player is loading. Loaded: 100.00% 0:00 PlayBack to start Stream Type LIVE Current Time 0:00 / Duration 0:08 1x Playback RatePfizer reposted this
Chris Boshoff, MD, PhD, FMedSci 2mo2026 is a pivotal year for Pfizer R&D, and I’m pleased with the strong progress we made this quarter. Across Oncology, metabolic disease, and vaccines — regulatory decisions, key data readouts, and new study starts. A pipeline advancing with focus and with purpose. Each milestone is the result of years of rigorous science and the relentless commitment of our teams worldwide. AI is becoming embedded in the fabric of R&D at Pfizer — helping accelerate discovery, sharpen decisions, and unlock insights from data at a scale and speed that would have been unimaginable just a few years ago. The future of medicine will be built at this intersection of bold science and intelligent technology. Thank you to the Pfizer R&D teams and partners worldwide who are making this happen — every day, for patients everywhere. The best is ahead.
777 53 Comments Like Comment Share7,097,553 followers
2moPfizer began 2026 with focus, confidence, and an unwavering commitment to patients. As we report our first quarter earnings, that commitment remains stronger than ever — driving us to deliver breakthroughs that change patients' lives today and into the future.
Albert Bourla Albert Bourla is an Influencer 2moPfizer started 2026 with focus and speed. Our first quarter results reflect what this team can deliver when we are aligned on what matters: strong commercial performance, meaningful pipeline progress, AI accelerating how we work across the organization and more. Every day we move faster is a day a patient gets an answer sooner. I am grateful to my colleagues for the remarkable work behind these results, and for remaining clear-eyed about our purpose. Read more: https://lnkd.in/emy9sT3D
Play Video Video Player is loading. Loaded: 29.37% 0:00 PlayBack to start Stream Type LIVE Current Time 0:00 / Duration 0:55 1x Playback Rate7,097,553 followers
2moWhen treating cancer, time is critical. That’s what makes the use of AI in oncology so pivotal. Today, AI is helping researchers identify potential clinical trial participants earlier, before critical windows close. The goal: more patients gaining access to investigational therapies and accelerated drug discovery. Discover how AI is already reshaping cancer research: https://lnkd.in/eytQhGVd #AIinHealthcare #OncologyResearch #ClinicalTrials #InnovationInMedicine #Biopharma #HealthTech #PatientAccess
7,097,553 followers
3mo EditedScott and Natalie, medicinal chemists at Pfizer, and their lab work to create and isolate compounds to be tested as potential drug candidates. During this process, compounds must be closely monitored and extensively tested to confirm their purity and ensure they match the scientists’ intended design. Watch our latest #WhatsInMyLab to learn more about this process and some of the tools involved. #Science #Innovation
…more Play Video Video Player is loading. Loaded: 21.83% 0:00 PlayBack to start Stream Type LIVE Current Time 0:00 / Duration 1:48 1x Playback Rate7,097,553 followers
3mo EditedAs colorectal cancer rates rise in young adults, advances in science are offering new hope for patients. This story explores how updated screening guidelines, advances in precision medicine, along with strides in research and education, are helping to reshape what’s possible. Read more: https://lnkd.in/gAi7QYq4 #ColorectalCancerAwarenessMonth #ColorectalCancer #CancerResearch #PrecisionMedicine
7,097,553 followers
4mo EditedPfizer is proud to champion this initiative led by Amyloidosis Research Consortium. Pre-competitive initiatives like ASPIRE allow organizations to pool expertise, accelerate research, and address challenges that are too complex for any one company to solve alone. By focusing on shared goals—such as expediting suspicion and recognition of ATTR-CM—we hope to create impact at scale, ultimately benefiting patients and public health with the single goal to address health disparities and accelerate progress in diagnosis and care. Learn more here: Brighter Together: https://lnkd.in/epgMZ7YM
ASPIRE: Amyloidosis Industry Collaborative446 followers
4moASPIRE (Amyloidosis Stakeholder Partnerships for Improved Research and Equity) now has a home on LinkedIn. This community connects patient advocates, researchers, clinicians, and industry partners working to improve how amyloidosis is diagnosed and treated. Follow along for research updates, new publications, and news from across the amyloidosis landscape. This page will serve as a central resource for: • Updates on ASPIRE initiatives and research collaborations • Examples of partnership and shared impact in rare disease • Opportunities to engage with ongoing programs and discussions Follow ASPIRE to stay informed as collaboration continues to advance more equitable outcomes for people affected by amyloidosis. Learn more: arci.org/aspire
7,097,553 followers
4moToday we announced positive topline results from a Phase 2 study of our potential first-in-class IL4/13 and TSLP trispecific antibody in #AtopicDermatitis. Learn more about these encouraging results, and how they support Pfizer’s plan to advance a broad development program for Type 2 (Th2) inflammatory conditions, here: https://lnkd.in/eABvkvVk
Chris Boshoff, MD, PhD, FMedSci 4mo EditedPfizer has announced positive topline results from a Phase 2 study of our potential first-in-class IL4/13 and TSLP trispecific antibody in #atopicdermatitis. These results support advancement to Phase 3 development, with a pivotal study in atopic dermatitis planned to start this year. Read the press release here: https://lnkd.in/eJzzeQJw These data underscore the continued momentum of our pipeline and reflect Pfizer’s refreshed R&D strategy, focused on delivering breakthrough medicines across four core therapeutic areas, including Inflammation & Immunology. By targeting multiple pathways in a single molecule, this innovative biologic, discovered and developed in-house at Pfizer, has the potential to transform treatment paradigms in inflammatory conditions. We plan to advance a broad clinical development program across atopic dermatitis and other Th2-mediated inflammatory diseases, including asthma and COPD.
Play Video Video Player is loading. Loaded: 17.74% 0:00 PlayBack to start Stream Type LIVE Current Time 0:00 / Duration 0:18 1x Playback RatePharmaceutical Manufacturing
New York, New York
Pharmaceutical Manufacturing
New York, NY
Pharmaceutical Manufacturing
Palo Alto, CA
Biotechnology
Chapel Hill, NC
Pharmaceutical Manufacturing
Basel, Baselstadt
Pharmaceutical Manufacturing
Paris, France
Hospitals and Health Care
New Brunswick, NJ
Pharmaceutical Manufacturing
Cambridge, Cambridgeshire
Pharmaceutical Manufacturing
London, England
Biotechnology Research
Pharmaceutical Manufacturing
Indianapolis, Indiana
Chemical Manufacturing
Leverkusen, North Rhine-Westphalia
Pharmaceutical Manufacturing
North Chicago, Illinois
Pharmaceutical Manufacturing
Vollzeit
BiotechnologieAI & Machine LearningSonstige Stellen im IT-BereichForschung & EntwicklungLeitung & Koordination